{"abstract": "The eye care company Bausch & Lomb agreed on Monday to sell itself to Valeant Pharmaceuticals International of Canada for about $8.7 billion, sidestepping the lengthier process of an initial public offering.", "web_url": "https://dealbook.nytimes.com/2013/05/27/bausch-lomb-to-sell-itself-to-valeant-for-8-7-billion/", "snippet": "The eye care company Bausch & Lomb agreed on Monday to sell itself to Valeant Pharmaceuticals International of Canada for about $8.7 billion, sidestepping the lengthier process of an initial public offering.", "lead_paragraph": "7:54 p.m. | Updated  ", "print_section": "B", "print_page": "2", "source": "The New York Times", "multimedia": [], "headline": {"main": "Eye Care Company Is Being Sold to Valeant", "kicker": "DealBook", "content_kicker": null, "print_headline": "Eye Care Company Is Being Sold To Valeant", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Eyes and Eyesight", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "organizations", "value": "BAUSCH & LOMB INCORPORATED", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Warburg Pincus", "rank": 5, "major": "N"}], "pub_date": "2013-05-27T13:29:06+0000", "document_type": "article", "news_desk": "", "section_name": "Business Day", "byline": {"original": "By Michael J. de la Merced", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/70339b61-3775-5086-98fd-a02f0daf5234", "word_count": 652, "uri": "nyt://article/70339b61-3775-5086-98fd-a02f0daf5234"}